How are you interpreting the CASSIOPEIA findings when deciding whether to proceed to allogeneic stem cell transplant after MRD-negative remission with frontline tisa-cel in pediatric high-risk B-ALL?

Does the absence of prior relapse before SCT in a substantial proportion of patients change your threshold for recommending transplant after CAR-T response? Maude et al. DOI: 10.1200/JCO.2026.44.16_suppl.10000